Forty Seven Inc. Receives $5 Million Grant from The California Institute for Regenerative Medicine (CIRM) to Support Ongoing Clinical Trial in Acute Myeloid Leukemia

CIRM grant will support further development of Forty Seven Inc.'s CD47 antibody Hu5F9-G4 in an ongoing second trial for the treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome MENLO PARK, Calif., Dec. 6, 2017 -- (Healthcare Sales &Marketin... Biopharmaceuticals, Regenerative Medicine, Oncology Forty Seven, acute myeloid leukemia, Myelodysplastic Syndrome, stem cell
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

Myelodysplastic syndromes (MDS) are a series of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral blood cytopenias, and a propensity to transform to acute myeloid leukemia (AML) [1]. AML is a myeloid malignancy characterized by increased self-renewal, limited differentiation and deregulated proliferation of myeloid blasts. They may cause bone marrow failure and death within months or even weeks if diagnosis and treatment time is delayed. Recent studies showed that demethylating agents 5-azacytidine (AZA) and 5-aza-2-deoxycytidine (decitabine, DAC) may bring substantial survival...
Source: Leukemia Research - Category: Hematology Authors: Source Type: research
Myelodysplastic syndromes (MDS) is a heterogeneous group of hematopoietic stem cell disorders that are characterized by cytopenia and dysplastic changes in peripheral blood (PB) and bone marrow (BM) and a propensity to transform into acute myeloid leukemia (AML) [1]. The diagnosis of MDS is based on cytomorphology and cytogenetics. Good cytomorphological experience is required for a correct diagnosis of MDS, particularly lower-risk MDS. The French-American-British (FAB) classification [2] was the standard.
Source: Leukemia Research - Category: Hematology Authors: Tags: Research paper Source Type: research
Myelodysplastic syndromes (MDS) are clonal disorders of hematopoietic stem cells that mainly affect the elderly, characterized by ineffective hematopoiesis, leading to cytopenia, infections, and a significant reduction in the quality of life [1,2]. Intensive chemotherapy combined with hematopoietic stem cell transplantation (HSCT) is the only curative treatment for this disease. However, it's applicability in elderly patients is limited by comorbidities and poor performance status. Azacytidine (AZA) significantly reduces transfusion dependence, decreases the risk of transformation to acute myeloid leukemia (AML), and impro...
Source: Experimental Hematology - Category: Hematology Authors: Tags: Brief Communication Source Type: research
In this study, we aimed to characterize patient- and disease-based differences in MDS/CMML patients with and without SIAMs and explore the impact of SIAMs on progression and survival.
Source: Seminars in Hematology - Category: Hematology Authors: Tags: Research Article Source Type: research
We report here indiscriminate killing of CD123+ normal and acute myeloid leukemia / myelodysplastic syndrome cells by SL-401, a diphtheria toxin interleukin-3 fusion protein. SL-401 induced cytotoxicity of CD123+ primary cells/blasts from acute myeloid leukemia and myelodysplastic syndrome patients but not CD123- lymphoid cells. Importantly, SL-401 was highly active even in cells expressing low levels of CD123, with minimal effect on modulation of the CD123 target in acute myeloid leukemia. SL-401 significantly prolonged survival of leukemic mice in acute myeloid leukemia patient-derived xenograft mouse models. In addition...
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research
ConclusionsThe noted predictive value of serum 2-HG levels andIDH2 mutations on OS and LFS support the use of biomarkers and/or underlying cytogenetics in novel prognostic scoring systems for MDS.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
In patients with myeloid malignancies, such as acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS), relapse remains the main cause of treatment failure after allogeneic hematopoietic stem cell transplantation (allo-HSCT) [1-4]. Several studies addressing therapeutic strategies for relapse after allo-HSCT have shown that treatment is more effective when initiated at molecular relapse rather than at hematologic relapse [5]. Therefore, early detection of imminent relapse, ideally at a molecular level, is a prerequisite for successful therapeutic intervention and can be achieved by regular monitoring of minimal...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
This multicenter study evaluated a treosulfan-based regimen in children and young adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplant (HCT). Forty patients with median age 11 years (1-19) underwent allogeneic HCT for AML in first (n=18), second (n=11), third or greater remission (n=3); or MDS (n=8) using bone marrow (n=25), peripheral blood stem cells (n=5) or cord blood (n=9). The regimen consisted of body surface area (BSA)-based treosulfan 10 g/m2/day (BSA ≤ 0.5 m2), 12 g/m2/day (BSA> 0.5 – 1.0 m2), or 14 g/m2/day (BSA> 1.0 m2) on ...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Hematologic malignancies are more prevalent in older patients, and because of the increased rate of elderly in the population, the number of patients presenting with hematologic malignancy has increased [1]. The median ages of patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS), which are the most common indication for allogeneic hematopoietic transplantation (alloHCT), in this population are 69 and 76 years, respectively [2-4]. Despite the advent of the novel agents, alloHCT remains the only curative option for most of the common hematologic malignancies.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
This multicenter study evaluated a treosulfan-based regimen in children and young adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplant (HCT). Forty patients with median age 11 years (range, 1 to 19) underwent allogeneic HCT for AML in first (n  = 18), second (n = 11), and third or greater remission (n = 3) or MDS (n = 8) using bone marrow (n = 25), peripheral blood stem cells (n = 5), or cord blood (n = 9). The regimen consisted of body surface area (BSA...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Clinical Trials | Grants | Leukemia | Men | Myelodysplastic Syndrome | Pharmaceuticals | Stem Cell Therapy | Stem Cells